NCT05372614 2026-03-19
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Leon Berard
Rutgers, The State University of New Jersey
Columbia University
University of Southern California
Weill Medical College of Cornell University
SynerGene Therapeutics, Inc.
Dushu Lake Hospital Affiliated to Soochow University
Anaeropharma Science, Inc.
Herlev Hospital
Seattle Children's Hospital
Eisai Inc.
Synta Pharmaceuticals Corp.
Eisai Inc.
Adherex Technologies, Inc.
Exelixis